Krystal Biotech

Forecast & Rating11 analysts currently cover Krystal Biotech, with about 90.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $376.75, about 7.1% upside from the current price of $351.82. Price targets range from $284.00 to $474.00 — a wide spread, showing clear disagreement over just how much Krystal Biotech can rise. Historically, about 97.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Krystal Biotech closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.